A Phase 3, Randomized, Double-Blind, Placebo-Controlled Study of LY2951742 in Patients With Chronic Migraine - the REGAIN Study

Trial Profile

A Phase 3, Randomized, Double-Blind, Placebo-Controlled Study of LY2951742 in Patients With Chronic Migraine - the REGAIN Study

Active, no longer recruiting
Phase of Trial: Phase III

Latest Information Update: 10 Jun 2017

At a glance

  • Drugs Galcanezumab (Primary)
  • Indications Migraine
  • Focus Registrational; Therapeutic Use
  • Acronyms REGAIN
  • Sponsors Eli Lilly
  • Most Recent Events

    • 10 Jun 2017 Results published in the Media Release
    • 08 Jun 2017 According to an Eli Lilly media release, data from this trial will be presented at the American Headache Society (AHS) annual scientific meeting 2017.
    • 22 May 2017 Last checked against European Clinical Trials Database record.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top